临床数据表明，对于cdk4/6i治疗失败后的晚期HR+/HER2-乳腺癌患者，羟氯喹联合大剂量cdk4/6抑制剂哌柏西利（200 mg，每天一次）的 ...

细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂联合内分泌治疗已成为HR阳性HER-2阴性晚期或转移性乳腺癌的优选治疗方案。但随着 ...

Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...